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OBJECTIVES: InApril 2005, theFoodandDrugAdministration (FDA) issuedablackbox
warning (BBW) regarding the risks of using atypical antipsychotics (AAPs) for behav-
ioral disorders in elderly patients with dementia. The objective of the present study
was to investigate the impact of the BBW on the utilization of non-antipsychotic psy-
chotropic drugs (NAPDs) such as benzodiazepines, anticonvulsants, antidepressants,
and anti-dementia agents in non-institutionalized dementia population.METHODS:
Medical Expenditure Panel Surveys, from year 2004 through 2007, were used in this
study. Utilization rates of NAPDs pre-warning (2004-2005) and post-warning (2006-
2007) were tracked over a four-year time period for both the main sample and Medi-
care cohorts. Chi-Square tests andmultivariate logistic regression analyses were per-
formed to examinepre-post differences inutilization rates (definedas elderly patients
taking at least one medication associated with dementia) and gain insights into pat-
terns of NAPD use with respect to demographic, insurance and other factors.
RESULTS: NAPD use increased in the post-warning period for the main sample as
well as the Medicare sample during the time period covered. The increase, however,
was not statistically significant. Multivariate logistic regression in the main sample
showed a greater likelihood of individuals receiving anti-dementiamedications (Odds
Ratio, OR 1.976, p 0.0195) and benzodiazepines (OR3.046, p 0.0227) in the post-
warning period as compared to the pre-warning period. Similarly, dementia patients
had a greater likelihood of receiving anti-dementiamedications (OR 2.229, p0.0065)
in the post-warning period as compared to the pre-warning period in the Medicare
sample as well. CONCLUSIONS: The regulatory warnings and labeling changes re-
garding off-label use of atypical antipsychotics in dementia treatment might have
resulted in spillover compensatory shift in the use of NAPD in non-institutionalized
populations.
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OBJECTIVES: Extra-pyramidal symptoms (EPS) can be a treatment emergent adverse
event associated with the use of atypical antipsychotics (AAPs). Studies assessing the
economic burden of EPS in schizophrenia are scarce.This study aims to assess health
care resource use and costs associated with EPS in patients with schizophrenia using
Medicaid data METHODS: A retrospective analysis of Marketscan Medicaid Multi-
State Database (2004-2009) was conducted. Patientswith a diagnosis of schizophrenia
andnewly initiatedonAAPwere included. The indexdatewas thedateof thefirstAAP
prescription fill. Two cohorts were created based on the presence or absence of either
a diagnosis code for EPS or a prescription claim for a known medication to treat EPS
during the90dayspost-index. PatientswithEPSwerematched topatientswithoutEPS
using propensity scores. The number of hospitalizations, emergency room (ER) and
associated health care costs were assessed in the 12 months follow up. Regression
models were conducted to compare utilization and costs between the two groups.
RESULTS:Total sample sizewas 4602.Of those, 545 (11.8%) had EPS. Younger age (36.6
vs. 38.9 years, p0.0001), higher proportion of African American patients (58.9% vs.
55.4%, p0.03), and a higher rate of risperidone use as the index treatment (61.1% vs.
36.1%, p0.0001) were observed in the EPS group. After matching, baseline covariates
were similar betweengroups. Patientswith EPShada significantly higher likelihoodof
schizophrenia-related (OR1.62, 95%CI1.18-2.23, p0.003) and all cause hospitaliza-
tions (OR1.45, 95% CI1.12-1.88, p0.0042) compared to patients without EPS. The
difference in schizophrenia-specific total health care, hospitalization, and prescrip-
tion drug costs between patients with and without EPS was $2636 (95% CI$1270-
$4002), $1427 (95% CI$467-2388), and $860 (95% CI$480-$1239), respectively.
CONCLUSIONS: The presence of EPS in patients with schizophrenia is associated
with increased health care resource utilization and higher direct medical costs.
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OBJECTIVES: Major depressive disorder (MDD) is frequently debilitating. The
American Psychiatric Association recommends adjunctive atypical antipsychotics
(AA) as a treatment option when response to antidepressants is inadequate. This
study compared medical costs and hospitalizations among MDD patients treated
with FDA-approved adjunctive AA. METHODS: This retrospective analysis used
medical and pharmacy claims data and enrollment information from a large US
health plan. Subjects were adult commercial enrollees with depression (ICD-9-CM
296.2x, 296.3x, 296.82, 300.4, 311) augmenting antidepressant therapy with an AA
(aripiprazole, olanzapine, or quetiapine) from 1/1/2004-1/31/2010. Subjects were
continuously enrolled for 6-month pre- and 12-month post-augmentation periods.
Those with schizophrenia or bipolar disorder were excluded. Post-augmentation
outcomes were all-cause and mental health (MH-) related medical costs and hos-
pitalizations. Costs and hospitalizations were modeled with generalized linear
models (gamma distribution, log link) and logistic regression, respectively. Regres-
sions controlled for dose, demographics, and general andMH-related health status.
Outpatient pharmacy costs were not assessed. RESULTS: 10,292 subjects were
identified across AA cohorts: aripiprazole, n3,849; olanzapine, n1,033; and que-
tiapine, n5,410. Mean age was 44.111.6 years and 70.3%were female. Compared
with the aripiprazole cohort, regression results showed that the olanzapine cohort
had higher predicted all-cause (1.22, p0.004) and MH-related (1.33, p0.002) med-
ical cost ratios and higher odds of all-cause (1.58, p0.001) and MH-related (1.81,
p0.001) hospitalizations. The quetiapine cohort also had higher predicted all-
cause (1.27, p0.001) and MH-related (1.23, p0.001) medical cost ratios and higher
odds of all-cause (1.65, p0.001) and MH-related (1.78, p0.001) hospitalizations.
Mean predicted all-cause andMH-relatedmedical costs, respectively, were $11,401
and $2,495 for aripiprazole, $13,905 and $3,316 for olanzapine, and $14,513 and
$3,072 for quetiapine. CONCLUSIONS: Compared with adjunctive olanzapine or
quetiapine, adjunctive aripiprazole was associated with lower mean all-cause and
MH-related medical costs and with lower odds of all-cause and MH-related hospi-
talizations in patients with depression.
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OBJECTIVES: A conspiracy between Mylan Laboratories and its active-ingredient
suppliers during the late 1990s resulted in the exit of manufacturers from the
lorazepammarket and a collusive price increase. The objectives were to 1) analyze
the market structure for lorazepam before and after the conspiracy; 2) measure
lorazepam prices before and after the conspiracy; and 3) estimate the social cost of
the conspiracy.METHODS: Data sources were the Medicaid State Drug Utilization
Data maintained by the Centers for Medicare & Medicaid Services (CMS) and the
First DataBank®National Drug File. The four-firmconcentration ratio (CR4) and the
Herfindahl-Hirschman index (HHI) for the Medicaid lorazepam market were mea-
sured from 1991 through 2009. Average quarterly per-claim pharmacy reimburse-
ment, as a proxy for average drug price, was computed. Average wholesale prices
(AWPs) for specific drug formswere obtained fromFirst DataBank®. Three separate
methodswere used to estimate overallMedicaid and social cost. RESULTS:CR4 and
HHI rose from 53 and 906, respectively, in 1991 to 87 and 2234 in 2009. In 1997, the
average spending per generic lorazepamprescription byMedicaidwas $7.00; it was
$30.24 in 1999. In 2009, spending per prescription was $8.48. AWPs for 3 common
dosage forms jumped identically for 8 firms on February 18, 1998. The estimated
total (12-year) cost of the conspiracy to Medicaid ranged from $613.7 - $713.5 mil-
lion (2009 $); and, overall for society, from$4.9 - $5.7 billion (2009 $).CONCLUSIONS:
Not all generic markets offer competitive prices. The lorazepam conspiracy was
very costly to Medicaid and other payers. This study has policy implications for
antitrust authorities aswell as physicians and payerswhoneed to have available to
them solid comparative-effectiveness research to justify the use of substitute
drugs in case of collusive pricing behavior in a single market such as lorazepam.
PMH81
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NEW INDICATION APPROVAL WITH CHANGE IN PRICE-PER-PRESCRIPTION OF
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OBJECTIVES: To evaluate the association of entries of generics/product-line exten-
sions and approval for clinical indications other than depression [such as general-
ized /social anxiety disorders (GAD/SAD)] with change in price-per-prescription of
brand selective-serotonin-reuptake-inhibitors (SSRIs) in the Texas Medicaid
program.METHODS: Utilization and expenditure variables from the Texas Medic-
aid summary database (1991-2009) were used. Price-per-prescription of a brand
SSRI for a given quarter was calculated as total expenditure (amount reimbursed)
divided by utilization (number of prescriptions dispensed). Two specifications of
autoregressive models were used with log-transformed price-per-prescription of a
brand SSRI as a ratio of current-to-previous quarter as the dependent variable. In
the first specification, generic entry of a brand SSRI was indicated by a dummy
variable. In the second specification, generic entry was measured by two continu-
ous variables - time to generic entry and time after generic entry. In both specifi-
cations, each of the events indicating entries of generics/product-line extensions
and approval for GAD and SADwere indicated by dummy variables. RESULTS: The
entry of sertraline was found to be positively associated (p0.05) with change in
price-per-prescription in both specifications of the Paxil® model. Time to patent
expiry was positively associated (p0.001) with change in price-per-prescription in
the Celexa® model. No other events were statistically significant. CONCLUSIONS:
Entries of generics/product-line extensions and approval for new clinical indica-
tions were not associated with change in price-per-prescription for a majority of
brand SSRIs. Promotional strategies indicating market entries of new product-line
extensions and facets of usage other than depression may be useful in controlling
the reimbursement of SSRI brands.
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DO SALES OF PSEUDOEPHEDRINE PREDICT METHAMPHETAMINE-RELATED
HOSPITALIZATIONS?
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OBJECTIVES: The illicit production of methamphetamine from the precursor
chemical pseudoephedrine (PSE) in domestic clandestine laboratories fuels a sig-
nificant portion of the domestic methamphetamine supply. Although states and
the federal government have taken steps to control access to PSE, it continues to be
available as a non-prescription drug in all but two states. The purpose of this
project was to assess the relationship between PSE sales and indicators of meth-
amphetamine use, specifically methamphetamine-related hospital admissions, in
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Kentucky.METHODS: Regression models were calculated to predict methamphet-
amine-related hospitalizations from 2010 county level Kentucky data. Explanatory
factors include PSE sales (in grams), number of clandestine lab incidents reported,
USDA urban/rural indicator, methamphetamine-related arrests, number of con-
trolled substance (CS) prescriptions dispensed, and population. Data sources in-
clude the Kentucky All Schedule Prescription Electronic Reporting Program, the
Kentucky Inpatient Discharge Data Set, the Kentucky State Policy Crime in Ken-
tucky Report, and Clandestine Laboratory Surveillance System. RESULTS: PSE sales
were not associated with methamphetamine-related hospitalizations in this
model. The number of clandestine lab incidents reported, however, has a strong
positive impact on methamphetamine-related hospitalizations (p0.001). Meth-
amphetamine-related arrests also have a strong positive relationship to hospital-
ization (p0.001). Finally, use of controlled substances has a small but negative
impact on methamphetamine-related hospitalization (p0.05). CONCLUSIONS:
PSE sales data alone cannot be used to predictmethamphetamine use as evidenced
by methamphetamine-related hospitalizations. The number of clandestine lab in-
cidents, however, reported is strongly associated with methamphetamine-related
hospitalizations. These findings suggest that policies aimed at reducing clandes-
tine labs may have a significant impact on indicators of methamphetamine use.
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COMPARISON OF TOTAL HEALTH CARE COSTS BETWEEN REMITTERS AND
NON-REMITTERS FOR SCHIZOPHRENIA PATIENTS FROM A PROSPECTIVE
LONGITUDINAL, OBSERVATIONAL STUDY IN THE PRESENCE OF MISSING DATA
Zhu B, Xu L, Faries D, Shen W, Haynes V
Eli Lilly and Company, Inc., Indianapolis, IN, USA
OBJECTIVES:Missing data has presented challenges to health economic analyses,
especially for a long-term observational study with repeated measures of clinical
and economic outcomes. The aim of this analysis was to compare the total health
care costs between symptom remission and non-remission from a long-term, ob-
servational study using mixed-effects models with and without multiple imputa-
tions (MI) of missing data. METHODS: Data (N2282) used for this analysis were
from a 3-year observational study of patients treated for schizophrenia in the
United States between July 1997 and September 2003. Costs of mental health ser-
vices were obtained at enrollment and at 6-month intervals during the 3-year
follow up. Cohorts of remitters versus non-remitters at enrollment were created
using established criteria. Total costs for remitters and non-remitters were com-
pared using mixed-effects models with and without MI based on Markov chain
Monte Carlo with multivariate normality assumption (MI-MCMC) or fully condi-
tional specification with predictive mean match method (MI-FCS). All analyses on
costs were adjusted for patient’s demographics and comorbidities. RESULTS: The
majority of the patients were male (61.6%) and non-remitters (73.8%) with a mean
age of 42 years. Out of 2282 patients, 41.2% had at least 1 visit (out of 7 visits) with
missing costs data. Without MI, the total healthcare costs were estimated to be
$8689.6 for the non-remitters and $6730.0 for the remitters with a difference of
$1959.7 (95% CI: $790 - $3129.4) over a 6-month period (p0.001). The estimated
differences in total costs between remitters and non-remitters were $1763.3 over
the 6-month period with the MI-MCMC method (p0.004) and $1483.9 with the
MI-FCS method (p0.009). CONCLUSIONS: Significant differences in total costs
between remitters and non-remitters were obtained from this study using mixed-
effects models with and without MIs. Further analysis will be conducted to explore
MI for estimation of other costs and examine missingness mechanisms.
PMH84
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OBJECTIVES: To examine sources of error in claims-based adherence calculations
for LAI antipsychotics with potentially invalid days’ supply (DS) values and evalu-
ate the assumption that quantity-dispensed (QD) values are in product units.
METHODS: Pharmacy claims for single-dose LAI antipsychotics dispensed between
January 1, 2009 and December 31, 2010 were selected from a large US database.
Frequency distributions were generated for observed DS and QD values for each
product and dose. Observed QD values on premixed LAI antipsychotic claims were
divided by the product’s volume to test the assumption that QD was entered in
milliliters rather than units. After adjustment toQD for premixed LAI antipsychotic
claims, duration of therapy per injection was calculated for all LAI antipsychotics
as DS/QD. Calculated therapy duration was compared with the dosing interval in
the product’s package insert (PI). Percentage of claims with duration of therapy per
injection within the product’s PI range was calculated as a measure of the validity
of the observed DS value. RESULTS: For the 611,325 LAI antipsychotic claims ana-
lyzed, observed QD values ranged from 0.01 to 117, suggesting values that did not
always represent product units. After adjustment to QD for premixed LAI antipsy-
chotics, 98.5% of claims had an integer value for calculated quantity in product
units, supporting the assumption that premixed LAI antipsychotics’ quantities
were entered in milliliters. After adjustment, 21.5% of claims had a calculated
therapy duration per injection outside the PI range. Percentage of claims with
calculated therapy durations outside the PI ranged from 10.6% to 39.1% for pali-
peridone palmitate, 7.6% to 13.1% for risperidone long-acting injection, and 3.1% to
10.8% for olanzapine pamoate. CONCLUSIONS: Results raise concerns regarding
potentially invalid values in DS andQDfields. Algorithms for appropriate use of LAI
antipsychotic pharmacy claims in adherence calculations, quality measurement,
and cost analyses are recommended.
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OBJECTIVES: Uncertainty remains regarding the developmental courses of inat-
tentive (IN) and hyperactivity (HA) symptoms. Using group-based trajectory mod-
eling, we sought to identify distinct independent and joint IN/HA symptom trajec-
tories and their predictors. METHODS: A total of 1037 boys (mean age: 6.20.3
years) from low socioeconomic areas in Montreal were recruited in 1984 for the
Longitudinal and Experimental Study of Low Socioeconomic Status (SES) Boys in
Montreal. Teacher and mother ratings of subjects’ IN and HA symptoms were
collected annually at ages 6, and 10 to 15 using the Social Behavior Questionnaire,
where the higher of the two raters’ scores was taken as subject’s IN/HA score.
Numbers and probabilities of independent IN and HA trajectories were identified
using group-based semi-parametric mixture models. Joint IN/HA trajectories were
then constructed as the joint probabilities of independent IN/HA trajectories.
Multinomial logistic regressions were conducted to assess baseline parental and
subject behavioral problems as predictors of joint trajectories. RESULTS: Six and
five independent trajectories were generated for IN and HA symptoms, respec-
tively, constituting 30 joint trajectories. The most common independent IN trajec-
tory (29.5% of study sample) had a moderate number of IN symptoms at baseline
that increased slightly with age (moderate-slightly rising), whereas the most com-
mon independent HA trajectory (28.5%) was baseline moderate-sharply declining.
The most common joint trajectories were based on the co-occurrence of a moder-
ate-sharply rising IN trajectory, and a low-/moderate-slightly rising HA trajectory
(17% vs. 14%). Subjects’ aggressiveness, conduct-, oppositional-, and anti-social
problems (p0.001), and paternal SES (p0.01) were significant predictors of joint
trajectories. CONCLUSIONS: Group-based trajectory modeling may be a useful
time-dependent pattern recognition tool. It enabled the identification of distinct
independent and joint IN/HA trajectories in age-related developmental courses.
Assessing baseline behavioral problems and paternal SES may help identify and
target interventions for young boys at risk of high-level IN/HA symptoms early on.
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OBJECTIVES: To demonstrate a unique approach to modeling long-term time-on-
therapy and cardiovascular disease (CVD) outcomes of patientswith schizophrenia
treated with atypical antipsychotics (AAPs). METHODS: A 5-year Markov cohort
analysis among adult patients with schizophrenia was undertaken to compare
time-on-therapy and CVD outcome differences lurasidone, generic-olanzapine,
aripiprazole, quetiapine, and ziprasidone. Modeled health states were: patients on
initial AAP; patients switched to a second composite-AAP; and patients on clozap-
ine after failing a second composite-AAP. The composite-AAP health state simu-
lated frequent treatment switching and was operationalized by averaging out-
comes, costs, and discontinuation rates (for transition probabilities) of the AAPs.
Patients discontinuing composite-AAP due to lack of efficacy were switched to
clozapine. Time-on-therapy was modeled using sub-states based on time of
switching. Baseline characteristics of themodeled cohort, data for discontinuation
rates, and averageweight changewere obtained fromCATIE, a comparative clinical
trial of lurasidone vs quetiapine XR, and an open-label study comparing aripipra-
zole and olanzapine. Relative risk of diabetes obtained from a retrospective anal-
ysis predicted CVD events using Framingham BMI risk equations. RESULTS:Over 5
years, patient time-on-therapy for the initial-AAP, composite-AAP, and clozapine,
respectively, was 0.85, 3.13, 1.01 years (lurasidone); 1.00, 2.98, 1.02 (generic-olan-
zapine); 0.51, 3.41, 1.08 (aripiprazole); 0.47, 3.45, 1.08 (quetiapine); and 0.54, 3.37,
1.09 (ziprasidone). In a 10,000 patient cohort, there were 407, 434, 415, 416, and 412
CVD events, respectively, in the lurasidone, generic-olanzapine, aripiprazole, que-
tiapine, and ziprasidone arms. CONCLUSIONS: This long-term Markov cohort
model simulates multiple treatment switches by using a composite health state
from sub-states and also enabled outcome assessment of time-dependent patient
characteristics, such as CVD events. The results were consistent with published
Markovmicro-simulationmodels showing that lurasidone and generic-olanzapine
had favorable discontinuation rates and that lurasidone and ziprasidone had fewer
CVD events. This analysis represents an effective alternative for modeling cohort-
level outcomes.
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CROSS-CULTURAL ADAPTATION OF A RESEARCH VERSION OF THE REY
AUDITORY VERBAL LEARNING TEST (RAVLT) INTO (US) SPANISH
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OBJECTIVES: The Rey Auditory Verbal Learning Test (RAVLT) was developed to
evaluate verbalmemory. The standard form comprises a 15-word list (List A) learn-
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